GPX4 and gastric adenocarcinoma: GPX4, a key regulator of ferroptosis, has been recognized as a prognostic biomarker for patients undergoing neoadjuvant chemotherapy (Sha et al., 2021), and is associated with the growth and metastasis of gastric adenocarcinoma (Cheng et al., 2024).